Log in

Relevant bibliographies by topics / Lipoproteins and coronary heart disease

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Lipoproteins and coronary heart disease'

Author: Grafiati

Published: 4 June 2021

Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Lipoproteins and coronary heart disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Lipoproteins and coronary heart disease"

1

Schaefer, Ernst J., and Margaret E. Brousseau. "DIET, LIPOPROTEINS, AND CORONARY HEART DISEASE." Endocrinology and Metabolism Clinics of North America 27, no. 3 (September 1998): 711–32. http://dx.doi.org/10.1016/s0889-8529(05)70035-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Clifton, P. M. "Postprandial Lipoproteins and Coronary Heart Disease." European Journal of Cardiovascular Prevention & Rehabilitation 1, no. 3 (October 1, 1994): 197–201. http://dx.doi.org/10.1177/174182679400100302.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lamprea-Montealegre, Julio A., Robyn L. McClelland, Morgan Grams, Pamela Ouyang, Moyses Szklo, and Ian H. de Boer. "Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease." Heart 104, no. 17 (February 22, 2018): 1455–60. http://dx.doi.org/10.1136/heartjnl-2017-312794.

Full text

Abstract:

ObjectiveThis study sought to characterise the main dyslipidaemic phenotypes present in chronic kidney disease (CKD) and their association with coronary heart disease (CHD) risk.MethodsAnalyses included 6612 individuals in the multiethnic study of atherosclerosis free of CHD at baseline. CKD was defined as an estimated glomerular filtration rate (eGFR) of 15 to <60 mL/min/1.73 m2 (stages 3–4). Principal component analyses were used to characterise the main dyslipidaemic phenotypes of CKD accounting for the correlation among different lipoproteins and lipoprotein particles. CHD was defined as incident myocardial infarction, angina followed by revascularisation, resuscitated cardiac arrest or CHD death.ResultsCHD developed in 303 individuals (5%) with eGFR ≥60 and in 72 individuals (12%) with CKD (p for difference <0.001). A dyslipidaemic phenotype (principal component 1 (PC1)) consisting of elevations in triglycerides, triglyceride-rich lipoproteins (VLDL particles), small LDL particles and reductions in HDL particles, was more common in those with CKD, compared with those without CKD (p for difference <0.001). This phenotype was also more strongly associated with CHD in those with CKD: adjusted HRs (95% CIs) per SD increase in PC1 1.13 (95% CI 1.00 to 1.27; P=0.05) and 1.51 (95% CI 1.17 to 1.94; P<0.001) in eGFR ≥60 and CKD, respectively (P for interaction=0.05).ConclusionIn individuals with mainly stage 3 CKD, a dominant lipid phenotype consisting of triglyceride-rich lipoproteins and other closely correlated lipoproteins is strongly associated with CHD risk. Future studies should investigate whether modification of the components of this phenotype leads to a reduction in the CHD burden in individuals with CKD.

APA, Harvard, Vancouver, ISO, and other styles

4

BARTER, P. J. "High density lipoproteins and coronary heart disease." Australian and New Zealand Journal of Medicine 21, no. 3 (June 1991): 299–301. http://dx.doi.org/10.1111/j.1445-5994.1991.tb04693.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Barter, P. J., and K. A. Rye. "High-Density Lipoproteins and Coronary Heart Disease." European Journal of Cardiovascular Prevention & Rehabilitation 1, no. 3 (October 1, 1994): 217–21. http://dx.doi.org/10.1177/174182679400100306.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Barter, P. J., and K. A. Rye. "High density lipoproteins and coronary heart disease." Atherosclerosis 121, no. 1 (March 1996): 1–12. http://dx.doi.org/10.1016/0021-9150(95)05675-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ahmed, Munir. "CORONARY HEART DISEASE;." Professional Medical Journal 21, no. 06 (December 10, 2014): 1171–73. http://dx.doi.org/10.29309/tpmj/2014.21.06.2250.

Full text

Abstract:

Objective: This study was done to find any correlation among total cholesterol, triglycerides, low density lipoprotein cholesterol and high density lipoprotein cholesterol estimated in serum of offsprings of coronary heart disease patients. Study Design: A cross sectional comparative study. Patients and Methods: Two hundred and fifty (250) subjects having parents with coronary heart disease were selected from Punjab Institute of Cardiology Lahore. The serum total cholesterol, triglycerides, low density lipoprotein cholesterol, and high density lipoprotein cholesterol were estimated. Coefficient of variation was calculated to find whether observations in one series vary correspondingly with observations in another series. Results: Highly significant positive correlation was found between total cholesterol and triglycerides, and, total cholesterol and low density lipoprotein cholesterol. Highly significant negative correlation was found between low density lipoprotein cholesterol and high density lipoprotein cholesterol. Correlation between TG and LDL-c was also significant. Conclusions: Serum total cholesterol, triglycerides, low density lipoprotein cholesterol and high density lipoprotein cholesterol have strong association with one and other. For prediction, prevention and management of coronary heart disease it is important to estimate and observe the correlation among these parameters.

APA, Harvard, Vancouver, ISO, and other styles

8

Miller, N. E. "Plasma Lipoproteins, Antihypertensive Drugs and Coronary Heart Disease." Journal of Cardiovascular Pharmacology 7 (1985): S105—S109. http://dx.doi.org/10.1097/00005344-198507002-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Katan, M. B., P. L. Zock, and R. P. Mensink. "Dietary oils, serum lipoproteins, and coronary heart disease." American Journal of Clinical Nutrition 61, no. 6 (June 1, 1995): 1368S—1373S. http://dx.doi.org/10.1093/ajcn/61.6.1368s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bittner, Vera. "Atherogenicity of Postprandial Lipoproteins and Coronary Heart Disease." Endocrinologist 4, no. 5 (September 1994): 359–72. http://dx.doi.org/10.1097/00019616-199409000-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Lipoproteins and coronary heart disease"

1

Shafi, Shahida. "The uptake of low density lipoproteins by vessel walls in relation to atherosclerosis." Thesis, King's College London (University of London), 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.338174.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Peel, Andrew. "The development and application of a novel assay for apolipoprotein B-48." Thesis, University of Surrey, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.334576.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Isherwood, Samantha Gail. "Apolipoprotein B-48 as a marker for chylomicrons and their remnants : studies in the postprandial state." Thesis, University of Surrey, 1996. http://epubs.surrey.ac.uk/842779/.

Full text

Abstract:

Dietary-derived lipoproteins, chylomicrons (CM) and CM remnants (CMR), have been implicated in the progression of cardiovascular disease. Retinyl esters are currently the most widely used method for monitoring CM metabolism. The availability, however, of a specific antisera to apo B-48, the protein uniquely associated with dietary-derived lipoproteins, has allowed more extensive investigation of CM and CMR metabolism. The effect of habitual, moderate levels of exercise (3 to 4 exercise sessions a week) on the lipaemic response to meals of varying fat content was assessed in young male subjects. Apo B-48, triacylglycerol (TAG) and retinyl ester were used as markers for CM particles. Active subjects had a lower response than an inactive group in all parameters measured over time after the meals. Lipoprotein lipase (LPL) activity levels measured at the end of the postprandial period were higher in the active group. The area under the time-response curves (AUC) for apo B-48 in the inactive group increased with increasing fat content of the meals, whereas the AUC for apo B-48 was the same after each meal in the active group. Validation of a specific ELISA for apo B-48 was carried out. Cross-reactivity of the antisera with low levels of apo B-100, the protein present on endogenous lipoproteins, was ruled out. The assay was specific and sensitive for measuring apo B-48 concentrations in the CM-enriched fractions. The use of the assay in the current format for plasma samples could not be fully assessed due to difficulties with isolating a pure, concentrated sample of apo B-100 and problems with reactivity between the secondary antibody used in the assay and plasma proteins. The assay was useful for showing postprandial patterns of changes in apo B-48 levels in plasma. The effects of meal frequency on the lipaemic response to a high fat test meal challenge were assessed in an intervention study. A nibbling diet was found to cause differences between the response of various parameters after the meal (NEFA-AUC, LPL activity, infranatant-TAG AUC and time to peak) compared with the normal meal frequency. The size and density distribution of CMR in plasma were investigated. Apo B-48 was found in the IDL and LDL fractions in both the postabsorptive and postprandial states. A comparison between the retinyl ester and apo B-48 responses in the postprandial studies showed that the time to peak retinyl ester level was delayed compared to apo B-48 and TAG. The importance of apo B-48 for studying the metabolism of CM and CMR metabolism was demonstrated.

APA, Harvard, Vancouver, ISO, and other styles

4

Junit, Sarni Mat. "Regulation of human HMGCoA reductase and LDL receptor gene expression in relation to coronary heart disease and diet." Thesis, University of Nottingham, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.387665.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bolton, Jennifer Lynn. "Candidate genotypes in prediction of coronary heart disease." Thesis, University of Edinburgh, 2011. http://hdl.handle.net/1842/15877.

Full text

Abstract:

Introduction There has been much discussion on personalised medicine; however use of genotype in risk prediction for coronary heart disease (CHD) has not resulted in appreciable improvements over non-genetic risk factors. The primary aim was to determine whether candidate single nucleotide polymorphisms (SNPs) identified from genome-wide association studies improved prediction of CHD over conventional risk factors (CRF). The secondary aim was to determine whether the use of apolipoproteins or lipoprotein(a) improved risk prediction of CHD. Methods Analyses used the Edinburgh Heart Disease Prevention Study (EHDPS), with 1592 men aged 30-59 and follow-up after 20 years; and the Edinburgh Artery Study (EAS), with 1592 men and women aged 54-75 and 15 years of follow-up. Candidate SNPs were identified by systematic literature reviews. CHD status was evaluated as severe (myocardial infarction or coronary revascularisation), and any (severe CHD, angina or non-specified ischaemic heart disease). Cox proportional hazards models were used to evaluate addition of candidate SNPs or lipids to models containing CRF. Results A group of genome-wide significant SNPs resulted in a non-significant improvement in C-index for severe CHD (0.038, p=0.082), and a significant improvement in C-index for any CHD (0.042, p=0.016); the associated net reclassification improvements (NRI) were 20.5% and 18.7%, respectively. Regression trees identified SNPs that were predictive of the remaining variance after adjusting for CRF; this resulted in a significant improvement in C-index for any CHD (0.031, p=0.008). The NRI were 11.0% and 9.6% for severe and any CHD, respectively. When compared with HDL cholesterol/total cholesterol, apolipoprotein AI/total cholesterol yielded a NRI of 3.3% for severe CHD. Lipoprotein(a) improved prediction of severe CHD, with a non-significant improvement in C-index (0.020, p=0.087), and NRI of 11.8%. Conclusion The results of this study indicate that a well selected group of candidate SNPs can improve risk prediction for CHD over-and-above CRF. The inclusion of lipoprotein(a), along with CRF, appeared to improve prediction of severe CHD, but not any CHD.

APA, Harvard, Vancouver, ISO, and other styles

6

Pocathikorn, Anothai. "Low density lipoprotein receptor-related protein (LRP) and its mRNA : influence of genetic polymorphisms, a fat load and statin therapy /." Connect to this title, 2005. http://theses.library.uwa.edu.au/adt-WU2006.0117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Mbewu, Anthony David. "Clinical and laboratory studies of lipoprotein (A) in coronary heart disease." Thesis, Queen Mary, University of London, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.283731.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Harris, Christopher Peter David. "Lipoprotein quality, anti-(xanthine oxidase) antibodies and coronary heart disease risk." Thesis, University of Bath, 1995. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.760669.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Masoud, Mohamed Abdulsalam. "Validation of a recently proposed equation for the estimation of small, dense LDL particles from routine lipid measures in a population of mixed ancestry South Africans." Thesis, Cape Peninsula University of Technology, 2016. http://hdl.handle.net/20.500.11838/2490.

Full text

Abstract:

Thesis (MSc (Biomedical Technology))--Cape Peninsula University of Technology, 2016.
Cardiovascular diseases (CVD) are the leading cause of global mortality, of which over 75% occurred in low- and middle-income countries such as South Africa. The lipid profile, specifically decreased levels of high density lipoprotein cholesterol (HDL-C), elevated triglyceride levels and the presence of small-dense low density lipoprotein (sdLDL) has been reported associated with CVD. An increased number of sdLDL is also common in metabolic syndrome (MetS), visceral obesity and diabetes mellitus, the last a known risk factor for CVD. The modification of low density lipoprotein (LDL) size, or number of sdLDL particles, has been reported to significantly reduce CVD risk, but not conclusively so and needs further investigation. In this regard, sdLDL particles are seldom estimated routinely for clinical use because of financial and other limitations. Currently, an alternative approach for estimating sdLDL is to use equations derived from routine lipid measures, as has been proposed by several groups. However, there is a need for extensive evaluation of this equation across different ethnic and disease groups, especially since reports showed an inadequate performance of the equation in a Korean population. The aim of this study was to assess the performance of a recently proposed equation for the estimation of sdLDL in healthy and diabetic mixed ancestry South Africans. Furthermore, we also investigated the role of sdLDL as a cardiometabolic risk factor, as measured against known risk factors such as the glycemic and lipid profiles.

APA, Harvard, Vancouver, ISO, and other styles

10

Roland, Alexander. "Possible protection against cardiovascular disease by plant antioxidants : flavonoids, copper and low density lipoprotein." Thesis, University of Reading, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.342119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Lipoproteins and coronary heart disease"

1

Hudson, Kenneth. Lipids, lipoproteins and coronary heart disease. [s.l: The Author], 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

High density lipoproteins, dyslipidemia, and coronary heart disease. New York: Springer, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Schaefer, Ernst J., ed. High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-1059-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mangiapane, E. H. Diet, lipoproteins and coronary heart disease: A biochemical perspective. Nottingham: Nottingham University Press, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mangiapane, E. H. Diet, lipoproteins andcoronary heart disease: A biochemical perspective. Nottingham: Nottingham University Press, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Colloquium, Fondation de recherche sur l'athérosclérose de la communauté française de Belgique International. Lipoproteins and atherosclerosis. New York: Plenum Press, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Miller, Naomi. Triglyceride, high density lipoprotein, and coronary heart disease: January 1989 through February 1992 plus selected earlier literature : 1636 citations. Bethesda, Md: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Library of Medicine, Reference Section ; Washington, D.C. : Sold by the Supt. of Docs., U.S. G.P.O., 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kerry-Anne, Rye, ed. High density lipoprotein cholesterol: The new target ; a handbook for clinicians. 3rd ed. Edgbaston: Sherborne Gibbs, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

J, Pownall Henry, ed. Manual of lipid disorders: Reducing the risk for coronary heart disease. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

J, Pownall Henry, ed. Manual of lipid disorders: Reducing the risk of coronary heart disease. 2nd ed. Baltimore: Williams & Wilkins, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Lipoproteins and coronary heart disease"

1

Douste-Blazy, Ph, and H. U. Kloer. "Chapter 17. Hyperlipoproteinemia and Coronary Heart Disease." In Human Plasma Lipoproteins, edited by J. C. Fruchart and J. Shepherd, 379–90. Berlin, Boston: De Gruyter, 1989. http://dx.doi.org/10.1515/9783110873665-020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rader, Daniel J., and H. Bryan Brewer. "Lipids, Apolipoproteins and Lipoproteins." In Genetic factors in coronary heart disease, 83–103. Dordrecht: Springer Netherlands, 1994. http://dx.doi.org/10.1007/978-94-011-1130-0_6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Asztalos, Bela F. "High Density Lipoprotein Particles." In High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease, 25–32. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-1059-2_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Schaefer, Ernst J., and H. Bryan Brewer. "ATP Binding Cassette A1 Transporter Function and Tangier Disease." In High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease, 71–77. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-1059-2_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kellner-Weibel, Ginny, Margarita de la Llera-Moya, Sandhya Sankaranarayanan, and George H. Rothblat. "In Vitro Studies and Mass Flux of Cholesterol Between Serum and Macrophages." In High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease, 83–88. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-1059-2_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Brousseau, Margaret E. "Genetic Loci Influencing Plasma High Density Lipoprotein Cholesterol Concentrations in Humans." In High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease, 111–20. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-1059-2_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Schaefer, Ernst J. "Nutritional and Lifestyle Factors and High-Density Lipoprotein Metabolism." In High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease, 121–27. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-1059-2_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Brinton, Eliot A., and M. Nazeem Nanjee. "Effects of Ethanol Intake on High Density Lipoprotein Metabolism in Humans." In High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease, 129–38. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-1059-2_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lamon-Fava, Stefania. "Effects of Statins on HDL Metabolism." In High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease, 151–55. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-1059-2_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Chan, Dick C., P. H. R. Barrett, and Gerald F. Watts. "Therapeutic Regulation of High-Density Lipoprotein Transport in the Metabolic Syndrome." In High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease, 157–63. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-1059-2_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Lipoproteins and coronary heart disease"

1

Ahmad, Nafisah Ibrahim, Sri Lelyati C. Masulili, Robert Lessang, and Basuni Radi. "Low density lipoprotein levels linkage with the periodontal status patients of coronary heart disease." In BIOMEDICAL ENGINEERING’S RECENT PROGRESS IN BIOMATERIALS, DRUGS DEVELOPMENT, AND MEDICAL DEVICES: Proceedings of the First International Symposium of Biomedical Engineering (ISBE 2016). Author(s), 2017. http://dx.doi.org/10.1063/1.4976777.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pescador, R., R. Porta, R. Niada, M. Mantovani, and G. Prino. "DEFIBROTIDE DECREASES CHOLESTEROL CONTENT IN HYPERCHOLESTEROLEMIC RABBIT AORTA, WITH NO MODIFICATION OF PLASMA OR LIPOPROTEIN CHOLESTEROL." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643153.

Full text

Abstract:

Defibrotide was shown to stimulate the production of endogenous PGI2 from rat and hamster aortic tissue, as well as the production of PGi2 frcm the coronary vascular bed in the platelet perfused heart model. This effect was only seen in presence of platelets. Durirg the infusion period with Defibrotide thromboxane release remained unaffected while platelet cAMP rised. Defibrotide, was also able to reduce the secretion of ATP from platelets as well as to deaggregate platelet cluTps. It has been postulated that long-term administration of stable PGI^ metabolites or analogues could be a more useful means of enhancing cholesterol and cholesteryl ester mobilization out of the arterial “ foam” cell during early stages of cardiovascular disease. These observations prompted us to administer Defibrotide i.v. to cholesterol fed rabbits to verify if it could cause a decrease in cholesterol content of aortas. Aorta cholesterol was evaluated by gas chromatography. Plasma or lipoprotein lipids were assayed by enzymatic kits from Boehringer Biochemia. Plasma lipoproteins were separated by density gradient ultracentrifugation. Platelet aggregation was carried out with ADP using an optical aggregometer to find out the effective aggregatory concentration fifty (EC). Histology of the rabbit hearts was performed by optical microscopy on heart sections coloured with hematoxylin-eosine. Defibrotide caused a decrease (-49%, P < 0.05, vs. cholesterol fed rabbits treated with placebo) in cholesterol content of aortas with no modification of total plasma cholesterol, triglyceride and phospholipid. The cholesterol, triglyceride, phospholipid and protein of plasma lipoproteins were not affected too. The EC of rabbits treated with Defibrotide was 50 normalized (-9%, N.S. vs. control animals fed the normal diet and treated with placebo; cholesterol fed animals treated with placebo: -32%, P< 0.05 vs. control animals fed the normal diet). Vascular lesions in the hearts of animals treated with Defibrotide had a lower rate (33%) in comparison to that (87%) of animals fed with cholesterol and treated with placebo. It is concluded that the ability of Defibrotide to stimulate vascular PGI2 formation and to reduce platelet sensitivity could be helpful in reducing the amount of cholesterol in the cardiovascular system in atherosclerotic prone situations.

APA, Harvard, Vancouver, ISO, and other styles

3

Handayani, Egi Atika, Husnah, and Muhammad Ridwan. "The Relationship between Nutritional Status and Central Obesity with Low Density Lipoprotein (Ldl) Cholesterol Level in Coronary Heart Disease Patients at Rsudza Banda Aceh." In The 2nd Syiah Kuala International Conference on Medicine and Health Sciences. SCITEPRESS - Science and Technology Publications, 2018. http://dx.doi.org/10.5220/0008789701320137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Reed, Scott M., Min S. Wang, and Erica L. Curello. "Electrophoretic Mobility of Lipid Coated Nanoparticles: Understanding the Influence of Size and Charge on a Lipoprotein Particle Mimic." In ASME 2011 International Mechanical Engineering Congress and Exposition. ASMEDC, 2011. http://dx.doi.org/10.1115/imece2011-64158.

Full text

Abstract:

Elevated levels of low-density lipoprotein (LDL) are associated with increased risk of coronary heart disease (CHD). Although smaller LDL particles are more atherogenic, it is not clear how LDL particle size influences atherogenesis. Smaller particles may be more prone to macrophage uptake and plaque formation. Alternatively, increased rates of lipid oxidation may explain the atherogenic effects of smaller LDL. We have developed a mimic of LDL that allows independent examination of the effect of LDL size and oxidation. We have engineered LDL mimics using liposome-encapsulated gold nanoparticles, in which the size and surface charge are independently controlled during synthesis. Here we examine the effects of lipid composition on zeta potential and electrophoretic mobility of LDL mimics. Using these mimics, we explored the effect of the lipid coating on the nanoparticles including anionic lipids and oxidized lipids. Dynamic light scattering was used to determine the size of the mimics and gel electrophoresis was used to measure the mobility and calculate zeta potential. The charge of the lipid coating influenced the mobility and we anticipate this will influence how the mimics interacts with proteins.

APA, Harvard, Vancouver, ISO, and other styles

5

Aursnes, I., P. Smith, and H. Arnesen. "EPIDEMIOLOGICAL ASPECTS OF ANTITHROMBIN-III, SELENIUM AND LIPOPROTEIN COMPONENTS IN CORONARY DISEASE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643030.

Full text

Abstract:

The known risk factors for coronary disease can only “explain” a proportion of the incidence of the disease. Looking for supplementary risk factors we thus selected for detailed study both a group of patients with normal levels of risk factors (normo-tensives, non-smokers with normal serum cholesterol) and a group with high conventional risk factors, comparing both groups with an age and sex matched control group. Subgroups were formed by individuals aged below (young) and above (old) 60 years.Total- and HDL-cholesterol, apo-lipoproteins A-I and B and triglycerides showed co-variation with each others and with fatty acids in serum. With "factor analysis" seven "factors" were extracted and the factor scores for sub-groups were calculated. Two factors discriminated between young, high risk patients and controls. One was a positive risk factor and the other a negative one. The factors may be dependent on the existence of two unknown sub-groups of serum lipoproteins which were characterized by high concentrations of certain fatty acids.Coronary patients were found to have 9.1% higher antithrombin-III (AT-III) activity in their plasma than controls (p=0.037). Plasma selenium levels were slightly less in patients than in controls. There was a slight, but significant (r = 0.29 , p = 0.01 5) positive correlation between selenium and AT-III concentrations. Multivariate statistical anlysis indicated that selenium was significantly negatively correlated with disease.It is concluded that antithrombin-III tend to be high and that plasma selenium levels are relatively sub-normal in some coronary patients. It is also suggested that fatty acid analysis may be useful in the characterization of lipoproteins that are involved in the development of atherosclerosis.

APA, Harvard, Vancouver, ISO, and other styles

6

Lin, Shisong, Xiaodong Zhuang, Shiyun Huang, Yahui Liu, Linlin Shen, and Xinxue Liao. "Face Analysis for Coronary Heart Disease Diagnosis." In 2019 12th International Congress on Image and Signal Processing, BioMedical Engineering and Informatics (CISP-BMEI). IEEE, 2019. http://dx.doi.org/10.1109/cisp-bmei48845.2019.8966020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Pareek, Vishakha, and R. K. Sharma. "Coronary heart disease detection from voice analysis." In 2016 IEEE Students' Conference on Electrical, Electronics and Computer Science (SCEECS). IEEE, 2016. http://dx.doi.org/10.1109/sceecs.2016.7509344.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Mangathayaru, Nimmala, B. Padmaja Rani, V. Janaki, Lakshmi Sowmya Kotturi, Manasa Vallabhapurapu, and G. Vikas. "Heart Rate Variability for Predicting Coronary Heart Disease using Photoplethysmography." In 2020 Fourth International Conference on I-SMAC (IoT in Social, Mobile, Analytics and Cloud) (I-SMAC). IEEE, 2020. http://dx.doi.org/10.1109/i-smac49090.2020.9243316.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Runjing, Zhou, and Li Keyang. "Fisher classifier in diagnosis of coronary heart disease." In 2011 4th International Congress on Image and Signal Processing (CISP). IEEE, 2011. http://dx.doi.org/10.1109/cisp.2011.6100787.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Gonsalves, Amanda H., Fadi Thabtah, Rami Mustafa A. Mohammad, and Gurpreet Singh. "Prediction of Coronary Heart Disease using Machine Learning." In the 2019 3rd International Conference. New York, New York, USA: ACM Press, 2019. http://dx.doi.org/10.1145/3342999.3343015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Lipoproteins and coronary heart disease"

1

Dong, Guoqi, Mengye Lu, Xiaoliang Wu, Hao Chen, Hongru Zhang, and Yihuang Gu. Network meta-analysis of Traditional Chinese medicines for depression in coronary heart disease patients. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Wienke, Andreas, Anne M. Herskind, Kaare Christensen, Axel Skytthe, and Anatoli I. Yashin. The influence of smoking and BMI on heritability in susceptibility to coronary heart disease. Rostock: Max Planck Institute for Demographic Research, January 2002. http://dx.doi.org/10.4054/mpidr-wp-2002-003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Cai, Ruping, Yuli Xu, and Qiang Su. Meta-analysis of blood lipid reduction for patients with coronary heart disease by combination of pitavastatin and ezetimibe. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2021. http://dx.doi.org/10.37766/inplasy2021.5.0072.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ghambaryan, Anna. Heart Rate Variability, Catecholamine and Hemodynamic Responses During Rest and Stress in Coronary Artery Disease Patients: The PIMI Study. Fort Belvoir, VA: Defense Technical Information Center, January 2007. http://dx.doi.org/10.21236/ad1013978.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Pan, JianLue, Pangning Huang, Yuanwen Zhang, RongFa Huang, QiuCen Chen, and HuiBing Chen. Commonly Traditional Chinese Medicine in treatment of Coronary Atherosclerotic Heart Disease with Anxiety and Depression: a network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2021. http://dx.doi.org/10.37766/inplasy2021.4.0124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Liu, Chao, Jing Bai, Lanchun Liu, Jialiang Gao, and Jie Wang. Effectiveness and safety of Yufengningxin for treating coronary heart disease angina: A protocol for a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wang, Lina, Yangli Sun, Jie Zhan, Zhiyuan Wu, Peiming Zhang, Xiaopeng Wen, Shuqi Ge, Xu Han, and Liming Lu. Effects of exercise therapy on anxiety and depression in patients with coronary heart disease: a meta-analysis of a randomized controlled study. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2021. http://dx.doi.org/10.37766/inplasy2021.6.0017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Fan, Maoxia, Ying Tian, and Dong Guo. Efficacy and safety of Xinkeshu in the treatment of angina pectoris of coronary heart disease: A systematic review and meta-analysis protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2021. http://dx.doi.org/10.37766/inplasy2021.9.0026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Li, Xing-xing, Zong-jing Fan, Jie Cui, Rui Zhuang, Rong-peng Liu, Quan Lin, and Yang Wu. Cardiac rehabilitation of Baduanjin exercise in coronary heart disease after PCI: a protocol for systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2021. http://dx.doi.org/10.37766/inplasy2021.3.0065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Xu, Xiangmei, Wenna Yang, Xuan Chen, Yixuan Kong, Jie Wang, and Jinghui Zheng. Traditional Chinese Medicine Injection Combined with Conventional Western Medicine in Treating Coronary Heart Disease after PCI:A Protocol systematic review and meta analysis of overview. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2020. http://dx.doi.org/10.37766/inplasy2020.7.0087.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!